Acute esophagitis is a dose limiting side effect in patients undergoing concurrent chemoradiation therapy (CRT) for lung cancer. Severe (Radiation Therapy Oncology Group [RTOG] grade 3 or greater) esophagitis generally occurs in 15%-20% of non-small cell lung cancer (NSCLC) patients, which may result in treatment breaks that compromise local tumor control and poses a barrier to dose escalation > 66 Gy. Here, we report a novel contralateral esophagus sparing technique (CEST) that employs intensity modulated radiation therapy (IMRT) to reduce the incidence of severe esophagitis. We retrospectively reviewed the radiation charts of lung cancer patients receiving concurrent CRT in curative intent in the senior author’s practice from 1/2013 to 1/2014. All patients underwent custom immobilization, 4D CT simulation, IMRT planning with multicriteria optimization, and treatments with daily cone beam CT guidance. Adaptive planning was performed for tumor regression and other changes in patient anatomy during treatment. In addition to standard organs at risk, the esophageal wall contralateral (CE) to the tumor was contoured as an avoidance structure to guide driving a steep dose fall off gradient beyond the target volume. Esophagitis was recorded using the RTOG acute toxicity grading system. We identified 20 consecutive patients treated with concurrent CRT of at least 63 Gy in whom there was gross tumor within 1 cm of the esophagus. Median age was 69 years (range, 46-83 years). The majority of patients had stage III NSCLC (75%). Only 1 patient was treated with 63 Gy, all others received ≥66 Gy and the median radiation dose was 70.2 Gy (range, 63-72.15 Gy) delivered over 35 to 40 fractions. In all patients, >99% of the planning and internal target volumes were covered by at least 90% and 99% of prescription dose, respectively. Strikingly, no patient developed RTOG grade 3 esophagitis (0/20, 95% CL 0-16%) despite the high total doses delivered. The frequency of grade 0, 1, 2 esophagitis was 25%, 55%, and 20%, respectively. The median V45 and V55 of the CE was 1.8 cc and 0.3 cc, respectively. The average max esophageal dose was 70 Gy and the mean dose was 24 Gy, indicating effective sparing of the esophagus cross section by CEST. We report a simple yet effective method to avoid exposing the entire esophagus cross section to high doses, which mirrors the concept of posterior rectum sparing in the treatment of prostate cancer. Despite a median dose of 70 Gy in our cohort, we observed not a single case of grade 3+ esophagitis and few cases of grade 2 reactions. We, therefore, hypothesize that CEST improves the esophagus toxicity profile in lung cancer patients receiving concurrent CRT even at doses above the standard 60-66 Gy levels. A prospective multi-institutional trial of IMRT with CEST and dose escalation to 74 Gy will be conducted.